Histopathological efficiency of amifostine in radiation-induced heart disease in rats

Basit Öğe Kaydı
dc.authoridYucel, Neslihan/0000-0001-5845-2614;
dc.authorwosidErkal, Haldun Sukru/AAC-8209-2019
dc.authorwosidYucel, Neslihan/ABI-3412-2020
dc.authorwosidGürses, İclal/AAH-8552-2021
dc.contributor.authorGurses, I
dc.contributor.authorOzeren, M.
dc.contributor.authorSerin, M.
dc.contributor.authorYucel, N.
dc.contributor.authorErkal, H. S.
dc.date.accessioned2024-08-04T20:44:17Z
dc.date.available2024-08-04T20:44:17Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVE: Amifositine is a phosphorylated thiol that holds its radioprotective actions by several indirect mechanisms. The purpose of this study was to evaluate histopathologically whether amifositine administration prior to irradiation would have a long-term protective effect on heart tissue in an experimental rat model. METHODS: Single dose of 18 Gy radiation and sham radiation exposure were used in related groups. A dose of 200 mg/kg of amifostine was injected intraperitoneally 30 min prior to radiation exposure. Analyses were performed 6 months after irradiation. RESULTS: Vascular damage and vasculitis were significantly decreased in amifositine treatment group. At the same time, significant thickening of the medial layer was accompanied by vascular damage in irradiated groups. The number and severity of myocyte necrosis were diminished with amifostine. Nevertheless, it could not prevent epicardial and myocardial fibrosis. Severe myocardial fibrosis was observed prominently in three regions, particularly on the apex, tips of papillary muscles and in sites adjacent to the atrioventricular valves. The anti-inflammatory effect of amifostine was not seen. CONCLUSION: The development of vascular damage and vasculitis were prevented by the use of amifostine. There was a correlation between vascular damage and fibrosis development. According to histopathological results, amifostine could be used as a protective agent against the side effects of radiotherapy (Tab. 4, Fig. 2, Ref. 22).en_US
dc.identifier.doi10.4149/BLL_2018_011
dc.identifier.endpage59en_US
dc.identifier.issn0006-9248
dc.identifier.issn1336-0345
dc.identifier.issue1en_US
dc.identifier.pmid29405732en_US
dc.identifier.scopus2-s2.0-85042066009en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage54en_US
dc.identifier.urihttps://doi.org/10.4149/BLL_2018_011
dc.identifier.urihttps://hdl.handle.net/11616/98156
dc.identifier.volume119en_US
dc.identifier.wosWOS:000425181900011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherComenius Univen_US
dc.relation.ispartofBratislava Medical Journal-Bratislavske Lekarske Listyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectamifostineen_US
dc.subjecthistopathologyen_US
dc.subjectirradiationen_US
dc.subjectradiation-induced heart diseaseen_US
dc.titleHistopathological efficiency of amifostine in radiation-induced heart disease in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu